Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Gynecologic Oncology

Volumn 151, Issue 1, 2018, Pages 46-52

  Moore, Kathleen N ^a,b   O'Malley, David M ^c   Vergote, Ignace ^d   Martin, Lainie P ^e   Gonzalez Martin, Antonio ^f   Malek, Karim ^g   Birrer, Michael J ^h,i  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Katholieke Universiteit   (Belgium)

^e FOX CHASE CANCER CENTER   (United States)

^f MD ANDERSON CANCER CENTER   (Spain)

^g IMMUNOGEN INC   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antibody drug conjugate; Clinical trial; Combination therapy; Ovarian cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY DRUG CONJUGATE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; FOLATE RECEPTOR 1; MIRVETUXIMAB SORAVTANSINE; PLATINUM DERIVATIVE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; FOLR1 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CANCER RECURRENCE; CHEMOSENSITIVITY; CLINICAL EVALUATION; COHORT ANALYSIS; CONSTIPATION; CORNEA DISEASE; CORNEAL EPITHELIAL MICROCYST; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FALLOPIAN TUBE CANCER; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPESTHESIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFUSION RELATED REACTION; KERATITIS; KERATOPATHY; MAINTENANCE THERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; INCIDENCE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE; UTERINE TUBE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COHORT STUDIES; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FATIGUE; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOCONJUGATES; INCIDENCE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 85050978773     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2018.07.017     Document Type: Article

References (43)

1. Raja, F.A., Chopra, N., Ledermann, J.A., Optimal first-line treatment in ovarian cancer. Ann. Oncol. 23:Suppl. 10 (2012), x118–x127.
2. Chan, J.K., Brady, M.F., Penson, R.T., Huang, H., Birrer, M.J., Walker, J.L., et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian Cancer. N. Engl. J. Med. 374 (2016), 738–748.
3. Bouchard-Fortier, G., Rosen, B., Vyarvelska, I., Pasetka, M., Covens, A., Gien, L.T., et al. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer. Gynecol. Oncol. 140 (2016), 36–41.
4. Luvero, D., Milani, A., Ledermann, J.A., Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 6 (2014), 229–239.
5. Della Pepa, C., Tonini, G., Pisano, C., Di Napoli, M., Cecere, S.C., Tambaro, R., et al. Ovarian cancer standard of care: are there real alternatives?. Chin. J. Cancer 34 (2015), 17–27.
6. Markman, M., Bookman, M.A., Second-line treatment of ovarian cancer. Oncologist 5 (2000), 26–35.
7. Parmar, M.K., Ledermann, J.A., Colombo, N., du Bois, A., Delaloye, J.F., Kristensen, G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003), 2099–2106.
8. Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006), 4699–4707.
9. Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28 (2010), 3323–3329.
10. Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004), 1682–1691.
11. Coleman, R.L., Brady, M.F., Herzog, T.J., Sabbatini, P., Armstrong, D.K., Walker, J.L., et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18 (2017), 779–791.
12. Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30 (2012), 2039–2045.
13. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366 (2012), 1382–1392.
14. Mirza, M.R., Monk, B.J., Herrstedt, J., Oza, A.M., Mahner, S., Redondo, A., et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375 (2016), 2154–2164.
15. Coleman, R.L., Oza, A.M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 (2017), 1949–1961.
16. Elnakat, H., Ratnam, M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56 (2004), 1067–1084.
17. Kalli, K.R., Oberg, A.L., Keeney, G.L., Christianson, T.J., Low, P.S., Knutson, K.L., et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108 (2008), 619–626.
18. Vergote, I.B., Marth, C., Coleman, R.L., Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34 (2015), 41–52.
19. Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer 79 (1998), 121–126.
20. Marchetti, C., Palaia, I., Giorgini, M., De Medici, C., Iadarola, R., Vertechy, L., et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco. Targets Ther. 7 (2014), 1223–1236.
21. Chari, R.V., Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41 (2008), 98–107.
22. Chari, R.V., Miller, M.L., Widdison, W.C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53 (2014), 3796–3827.
23. Gunderson, C.C., Moore, K.N., Mirvetuximab soravtansine. FRa-targeting ADC; treatment of epithelial ovarian cancer. Drugs Future 41 (2016), 539–545.
24. Oroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 9 (2010), 2700–2713.
25. Goldmacher, V.S., Audette, C.A., Guan, Y., Sidhom, E.H., Shah, J.V., Whiteman, K.R., et al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS One, 10, 2015, e0117523.
26. Kovtun, Y.V., Audette, C.A., Ye, Y., Xie, H., Ruberti, M.F., Phinney, S.J., et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66 (2006), 3214–3221.
27. Ponte, J.F., Ab, O., Lanieri, L., Lee, J., Coccia, J., Bartle, L.M., et al. Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18 (2016), 775–784.
28. Moore, K.N., Martin, L.P., O'Malley, D.M., Matulonis, U.A., Konner, J.A., Vergote, I., et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 14 (2018), 123–136.
29. Moore, K.N., Borghaei, H., O'Malley, D.M., Jeong, W., Seward, S.M., Bauer, T.M., et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123 (2017), 3080–3087.
30. Moore, K.N., Martin, L.P., O'Malley, D.M., Matulonis, U.A., Konner, J.A., Perez, R.P., et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol. 35 (2017), 1112–1118.
31. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
32. Martin, L.P., Konner, J.A., Moore, K.N., Seward, S.M., Matulonis, U.A., Perez, R.P., et al. Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol. Oncol. 147 (2017), 402–407.
33. Pignata, S., CC, S., Du Bois, A., Harter, P., Heitz, F., Treatment of recurrent ovarian cancer. Ann. Oncol., 28, 2017 (viii51–viii6).
34. Morgan, R.D., Clamp, A.R., Evans, D.G.R., Edmondson, R.J., Jayson, G.C., PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother. Pharmacol. 81 (2018), 647–658.
35. Marth, C., Reimer, D., Zeimet, A.G., Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann. Oncol., 28, 2017 (viii36–viii9).
36. Parslow, A.C., Parakh, S., Lee, F.T., Gan, H.K., Scott, A.M., Antibody-drug conjugates for cancer therapy. Biomedicine, 4, 2016.
37. Moore, K.N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A., et al. FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol., 2018, 10.2217/fon-2017-0646.
38. Eaton, J.S., Miller, P.E., Mannis, M.J., Murphy, C.J., Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31 (2015), 589–604.
39. Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann. Oncol. 23 (2012), 1185–1189.
40. Bast, R.C., Thigpen, J.T., Arbuck, S.G., Basen-Engquist, K., Burke, L.B., Freedman, R., et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. Gynecol. Oncol. 107 (2007), 173–176.
41. Blackledge, G., Lawton, F., Redman, C., Kelly, K., Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br. J. Cancer 59 (1989), 650–653.
42. Herzog, T.J., Coleman, R.L., Ovarian cancer clinical trial endpoints: society of gynecologic oncology white paper. Gynecol. Oncol. 132 (2014), 8–17 http://www.medpagetoday.com/HematologyOncology/OvarianCancer/477552014.
43. O'Malley, D.M., Moore, K.N., Vergote, I., Martin, L.P., Gilbert, L., Martin, A.G., et al. Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. J Clin Oncol., 35, 2017 (Suppl): abstract 5553.